PDCD1 and head and neck squamous cell carcinoma: The current treatment of HNSCC has become increasingly diverse and individualized.Zandberg et al. [58] reported that hypoxia was increased in the anti-PD-1 resistant tumors of recurrent/metastatic patients with HNSCC.